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We describe here a case of disseminated cutaneous leish-
maniasis due to Leishmania major in a severely immuno-
compromised patient from Burkino Faso, Africa, who is in-
fected with human immunodeficiency virus–1. The skin
lesions failed to respond to full treatment courses of am-
photericin B, sodium stibogluconate, and liposomal ampho-
tericin B but were successfully treated with miltefosine, an
alkylphosphocholine analogue.
Over the past 2 decades, leishmaniasis, in particular visceral
leishmaniasis (VL), has been recognized as an opportunistic
disease in immunocompromised patients, particularly those in-
fected with HIV. Leishmania-HIV coinfection is very common
in areas where leishmaniasis is endemic and is identified as the
HIV pandemic spreads [1–3]. In contrast to the literature on
VL, only scarce data are available on cutaneous leishmaniasis
(CL) caused by dermotropic species in HIV-infected patients
[4, 5]. However, recent data from French Guiana suggests that
even in moderately immunosuppressed HIV-infected individ-
uals, CL is characterized by a higher rate of recurrence and is
more difficult to treat than it is in HIV-negative individuals
[5].
Treatment of leishmaniasis is difficult because of the limited
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number of effective antiparasitic agents available. Currently,
daily injections with pentavalent antimony, in the form of meg-
lumine antimonite, for 28 days is the standard treatment. So-
dium stibogluconate, another antimonial drug, has shown ex-
cellent efficacy at a dose of 20 mg/kg in a large clinical trial
that included immunocompetent young soldiers with either CL
(treatment course, 20 days) or VL (treatment course, 30 days)
[6]. In cases of resistance to antimony, low-dose amphotericin
B is administered (14 doses of 0.5 mg/kg, given on alternating
days). A more potent but much more expensive alternative is
intravenously administered liposomal amphotericin B (5 mg/
kg for 5 days). Because of the considerable toxicity of these
parenteral agents, alternative drugs are being evaluated, in-
cluding miltefosine. Miltefosine (hexadecylphosphocholine) is
an alkylphosphocholine analogue that was originally developed
as an antitumor agent but proved to be clinically ineffective
against tumors, with intolerable adverse effects. It interferes
with cell signal-transduction pathways and inhibits phospho-
lipid and sterol biosynthesis; although the exact mechanism of
action with regard to Leishmania has not been fully elucidated
[7]. Miltefosine is effective against Leishmania species in vitro
[8] and in vivo [9] and can be administered orally [10]. Its
efficacy and tolerability in immunocompetent individuals have
already been proven in earlier studies [11–13]. In a recent phase
III clinical trial for the treatment of VL in India, a cure rate
of 94% was reported [14]. Furthermore, it was recently shown
that among patients coinfected with Leishmania and HIV (al-
most all of whom were affected with VL) who had experienced
failure of standard leishmaniasis treatment, an initial response
rate of 64% and a cure rate of 43% was achieved during the
first treatment cycle with miltefosine [15]. Thus, miltefosine is
the first oral agent that appears to be highly effective and well
tolerated for the treatment of VL and CL [16, 17].
We describe an HIV-infected patient with severe dissemi-
nated cutaneous Leishmania coinfection that did not respond
to full courses of conventional treatment but was successfully
treated with miltefosine.
Case report. In April 2001, a formerly healthy 43-year-old
male immigrant from Burkina Faso, Africa, presented with a
6-month history of maculo-papulo-nodular lesions on his fore-
head and right leg and behind his left ear (figure 1, left panels).
He entered Switzerland in January 2001 and had occasionally
visited the Ivory Coast in the past. He reported no fever, mal-
aise, or weight loss (body weight, 60 kg). Except for the skin
lesions, the findings of physical examination were unremark-
able. Findings of laboratory tests were normal except for mild
Figure 1. Retroauricular region, right leg, and forehead of the patient before (left panels) and after (right panels) receiving miltefosine therapy (50
mg twice daily for 3 months).
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Figure 2. Hematoxylin and eosin–stained sample of a skin lesion
showing subepidermal infiltration with lymphocytes, plasma cells, and
histiocytes, which contain small inclusion bodies representing amastigotes
(arrow).
normochromic, normocytic anemia (hemoglobin level, 11.7 g/
dL; normal range, 13.5–17.2 g/dL) and lymphopenia (lympho-
cyte count, 0.77  103 cells/mL; normal range, 1.50–4.00 103
cells/mL).
The positive result of a screening test for HIV-1 was con-
firmed by Western blot analysis. The CD4 cell count was 10
cells/mL (CD4 cell percentage, 2%), and the HIV RNA load was
152,428 copies/mL. Combination antiretroviral therapy with
lamivudine, zidovudine, and nelfinavir was initiated, as well as
primary prophylaxis (with trimethoprime-sulfmethoxazole)
against Pneumocystis jiroveci (carinii) pneumonia.
Histological examination of specimens from skin lesions
showed subepidermal infiltrations with lymphocytes, plasma
cells, and histiocytes. In the histiocytes, small inclusion bodies
representing amastigotes could be seen (figure 2). The presence
of Leishmania DNA in samples from skin biopsies was re-
peatedly demonstrated by PCR [6]. In addition, the Leishmania
miniexon locus was amplified by PCR [18], and sequence anal-
ysis revealed 99.4% identity (312 of 314 bp) with Leishmania
major genomic sequences (e.g., GenBank accession number AC
121230) and the corresponding gene sequence of Leishmania
venezulensis (strain MHOM/VE/74/PM-H3 [GenBank acces-
sion number AY 155507]); the latter sequence differed by an
additional 2-nucleotide deletion. The sequence of the next best
match, Leishmania aethiopica, was only 75.5% identical to our
sequence. Repeated cultures of samples from skin biopsies were
positive; however, zymodeme analysis could not be performed,
because the isolates were lost due to microbial contamination.
Specific antibodies could be demonstrated by an immunofluo-
rescence antibody test based on intracellular amastigote forms
of Leishmania infantum (titer, 1:160; normal titer, !1:40),
whereas an ELISA based on soluble antigens of promastigote
stages of the same species had negative results. A CT scan of
the chest and abdomen showed generalized lymphadenopathy.
We initially suspected visceral involvement, but various at-
tempts to amplify Leishmania DNA from PBMCs, bronchoal-
veolar lavage fluid, and samples from biopsies of bone marrow
and subcarinal enlarged lymph nodes had negative results. In
addition, samples from lymph node and bone marrow biopsies
revealed negative histological findings, and cultures of those
samples were negative for Leishmania species. Thus, VL could
not be proven.
In addition to the skin lesions, the patient developed fever
and malaise. He was hospitalized, and amphotericin B therapy
(1 mg/kg/day) administered intravenously was started. Because
of nephrotoxicity, the dosage of amphotericin B was reduced
to 0.5 mg/kg and was later increased to 0.8 mg/kg subsequently.
The patient received therapy for a total of 21 days and received
an average dose of 0.64 mg/kg/day.
Two weeks after completion of amphotericin B therapy, the
patient developed new nodular lesions on his arms and face,
and the old lesions erupted again. On his right leg, a progressive
scaly exanthema appeared. Relapse of leishmaniasis was sus-
pected and then proven by histological analysis. Subsequently,
sodium stibogluconate, at a dosage of 20 mg/kg, was admin-
istered for 21 days. After a partial and brief improvement of
the skin lesions, the patient presented with rapidly progressing
lesions on his hands and face. His right lower leg was swollen,
and an ulcer developed. A course of liposomal amphotericin
B (AmBisome; Fujisawa Healthcare), given on days 1–5, 9, 16,
23, 30, and 37 (dosage, 5 mg/kg), was unsuccessful, and the
skin lesions progressed further. The patient had to be read-
mitted to the hospital for local antiseptic treatment with topical
paromomycin (20% ointment for 7 weeks), which showed very
limited effect.
Because 3 consecutive “classic” courses of established anti-
leishmaniasis treatment had failed, therapy with miltefosine
(Zentaris), at 100 mg per day (i.e., 2 capsules of 50 mg daily
by mouth), was initiated under a compassionate use protocol,
after written informed consent was obtained. After a few days,
a clear improvement of the skin lesions was apparent, and after
3 months, the patient experienced complete remission (figure
1, right panels). Apart from a mild elevation of the lactate
dehydrogenase level, no other laboratory abnormalities or ad-
verse effects were noted. To prevent relapse, we continued to
give the patient miltefosine therapy until his immune system
was partly restored. After a total of 18 months, the CD4 cell
count was 290 cells/mL (CD4 cell percentage, 10%), and mil-
tefosine therapy was stopped. The CD4 cell count was 1200
cells/mL at 1 year prior to the discontinuation of therapy, and
the viral load dropped to !50 copies/mL at 3 months after the
initiation of antiretroviral treatment and remained at that level
for the entire subsequent observation period. Two years later,
BRIEF REPORT • CID 2005:40 (15 June) • e123
the CD4 cell count was 317 cells/mL (CD4 cell percentage, 16%),
and no signs of CL or VL were detectable.
Discussion. The geographical origin of the patient, his
travel history (which was confined to Africa and Europe), and
the DNA sequence data suggest that the infectious agent should
be classified as L. major. The miniexon locus sequence of L.
venezulensis showed the same degree of identity, but recent
sequence data of the rDNA internal transcribed spacer regions
suggested that L. major and L. venezulensis are indeed very
closely related and led to the speculation that the latter species
might recently have been introduced into the New World in a
manner similar to that of L. infantum [19].
The clinical presentation of leishmaniasis varies widely in
both HIV-infected and immunocompetent patients [2, 3, 20].
In patients coinfected with HIV and Leishmania species, cu-
taneous lesions may occur before, after, or at the same time as
visceral lesions. However, exclusive cutaneous involvement does
occur, although such presentation is rare. The clinical picture
ranges from a few spontaneously healing lesions to diffuse ex-
ternal or internal disease, which may be accompanied by severe
mucous membrane involvement [21]. Concomitant opportun-
istic diseases can mask the clinical presentation.
When evaluating a treatment, the natural history of leish-
maniasis must be considered. In immunocompetent hosts, cu-
taneous lesions usually heal spontaneously in 1 month to 3
years, whereas lesions of mucocutaneous leishmaniasis and VL
rarely, if ever, heal without treatment. Until now, guidelines for
treatment of HIV-Leishmania coinfection have followed treat-
ment schemes used for leishmaniasis in immunocompetent pa-
tients. Because of high relapse rates, treatment of HIV-Leish-
mania coinfection requires close monitoring of efficacy, and
secondary prophylaxis for leishmaniasis should be considered.
A recent nonrandomized, retrospective, open-label trial with
37 patients has shown that pentavalent antimony therapy given
monthly prevented relapse in 93% of patients during the first
year [22]. A close correlation exists between CD4 cell count,
clinical presentation, and the evolution of disease. Up to one-
fourth of patients coinfected with HIV and Leishmania (man-
ifesting mainly as VL) who remain in a state of severe im-
munosuppression may die within 1 month after diagnosis [23].
Thus, it is of utmost importance to increase the CD4 cell count
by initiating potent antiretroviral therapy and to evaluate al-
ternative first-line treatments. There have been obvious favor-
able results of miltefosine treatment for CL and VL [11, 12,
14]. However, there is only limited experience with this drug
in HIV-infected patients [15], and, to our knowledge, the case
reported here is the first documented case of CL caused by L.
major that was treated with miltefosine. Interestingly, on the
basis of in vitro results, one would not have expected such a
good outcome, since, of 6 Leishmania species tested, L. major
was the least sensitive to miltefosine [8]. In summary, the pre-
sent case illustrates a spectacular sustained therapeutic response
of disseminated CL to miltefosine therapy in a severely im-
munocompromised patient with leishmaniasis refractory to
standard treatments.
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